Niagen Bioscience, Inc. Common Stock NAGE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.32M+52.9% | $4.13M-9.7% | $4.58M+26.8% | $3.61M-28.7% | $5.06M-29.5% | ||
| $116K-16.5% | $139K-11.5% | $157K-0.6% | $158K0.0% | $158K+4.6% | ||
| $1.72M-1.8% | $1.75M-0.5% | $1.76M+18.0% | $1.49M+38.4% | $1.08M+43.0% | ||
| $4.78M— | —— | —— | -$4K— | $0— | ||
| $85K— | —— | -$12K— | —— | -$1.32M-0.5% | ||
| $3.57M+75.5% | $2.04M-53.6% | $4.39M+36.1% | $3.22M+61.6% | $1.99M+247% | ||
| $2.48M— | —— | —— | $3.05M+44.7% | $2.11M— | ||
| -$101K-111% | $958K-27.4% | $1.32M+179% | -$1.67M-235% | $1.23M+11.4% | ||
| $169K+123% | -$746K-757% | -$87K+67.5% | -$268K-1,240% | -$20K-106% | ||
| -$12K+33.3% | -$18K-20.0% | -$15K-15.4% | -$13K0.0% | -$13K+27.8% | ||
| -$102K— | —— | —— | $95K— | $0— | ||
| $175K+192% | $60K+57.9% | $38K0.0% | $38K+2.7% | $37K-2.6% | ||
| -$241K-2.1% | -$236K-1.3% | -$233K-1.7% | -$229K+8.8% | -$251K-3.7% | ||
| $3.41M+170% | $1.26M+209% | -$1.16M-143% | $2.69M+232% | -$2.04M— | ||
| -$1.19M-276% | $679K-81.6% | $3.69M+195% | $1.25M-84.1% | $7.88M-8.2% | ||
| $5.8M— | —— | —— | —— | $0— | ||
| $5.25M+5,293% | -$101K-321% | -$24K+82.2% | -$135K-322% | -$32K+53.6% | ||
| $2.35M— | —— | —— | —— | $0— | ||
| $111K-51.3% | $228K+50.0% | $152K-95.9% | $3.75M+20.5% | $3.11M-17.9% | ||
| $0-100% | $2K-50.0% | $4K+33.3% | $3K0.0% | $3K+50.0% | ||
| $0-100% | $55K— | $0-100% | $6K0.0% | $6K-85.4% | ||
| -$2.29M— | $0-100% | $148K-96.0% | $3.74M+20.5% | $3.11M-17.2% | ||
| $1.76M+254% | $498K-86.9% | $3.82M-21.4% | $4.86M-55.7% | $10.96M-10.7% | ||
| $175K+192% | $60K+57.9% | $38K0.0% | $38K+2.7% | $37K-2.6% | ||
| $116K-16.5% | $139K-11.5% | $157K-0.6% | $158K0.0% | $158K+4.6% | ||
| $4.78M— | —— | —— | —— | $0— | ||
| —— | $495.75K0.0% | $495.75K0.0% | $495.75K0.0% | $495.75K— | ||
| —— | $16.5K0.0% | $16.5K0.0% | $16.5K0.0% | $16.5K-20.5% | ||
| $30K— | —— | —— | —— | $66K— | ||
| -$13K— | —— | -$16K— | —— | -$405K-194% | ||
| -$241K-2.1% | -$236K-1.3% | -$233K-1.7% | -$229K+8.8% | -$251K-3.7% | ||
| $3.41M+170% | $1.26M+209% | -$1.16M-143% | $2.69M+232% | -$2.04M— | ||
| $169K+123% | -$746K-757% | -$87K+67.5% | -$268K-1,240% | -$20K-106% | ||
| $114K— | —— | —— | —— | $0— | ||
| —— | $9.5K0.0% | $9.5K0.0% | $9.5K0.0% | $9.5K— | ||
| $173K— | —— | $164K+3.1% | $159K-8.1% | $173K— | ||
| —— | $166.25K0.0% | $166.25K0.0% | $166.25K0.0% | $166.25K-0.7% | ||
| -$12K+33.3% | -$18K-20.0% | -$15K-15.4% | -$13K0.0% | -$13K+27.8% | ||
| $85K— | —— | -$12K— | —— | -$1.32M-0.5% | ||
| —— | $0— | $0— | $0— | $0+100% | ||
| $494K— | —— | —— | —— | $0— | ||
| —— | $0— | $0— | $0— | $0-100% | ||
| —— | $73K0.0% | $73K0.0% | $73K0.0% | $73K+79.1% | ||
| $61K— | —— | $24K-82.2% | $135K+322% | $32K— | ||
| $0-100% | $2K-50.0% | $4K+33.3% | $3K0.0% | $3K+50.0% | ||
| $0-100% | $55K— | $0-100% | $6K0.0% | $6K-85.4% | ||
| $47K— | —— | —— | —— | $0— | ||
| —— | $1.37M0.0% | $1.37M0.0% | $1.37M0.0% | $1.37M— | ||
| -$102K— | —— | —— | $95K— | $0— | ||
| -$241K-2.1% | -$236K-1.3% | -$233K-1.7% | -$229K+8.8% | -$251K-3.7% | ||
| $226K-4.2% | $236K+1.3% | $233K+114% | $109K-63.1% | $295K+21.9% | ||
| —— | $281.75K0.0% | $281.75K0.0% | $281.75K0.0% | $281.75K— | ||
| $0— | —— | —— | —— | $1.13M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Niagen Bioscience, Inc. Common Stock generate?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $4.4M in operating cash flow over the trailing twelve months.
- Where does Niagen Bioscience, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
